847728-89-6

Basic information

• Product Name: (S)-[1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (S)-[1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER;(S)-tert-butyl 1-(4-broMophenyl)ethylcarbaMate;CarbaMic acid, [(1S)-1-(4-broMophenyl)ethyl]-, 1,1-diMethylethyl ester;tert-Butyl [(S)-1-(4-bromophenyl)ethyl]carbamate;(S)-N-Boc-1-(4-broMophenyl)ethylaMine
• CAS NO: 847728-89-6
• Molecular Formula: C₁₃H₁₈BrNO₂
• Molecular Weight: 300.2
• Mol File: 847728-89-6.mol
• Article Data: 62

Chemical Properties

• Boiling Point: 383.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.282±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.94±0.46(Predicted)
• CAS DataBase Reference: (S)-[1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-[1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(847728-89-6)
• EPA Substance Registry System: (S)-[1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER(847728-89-6)

Safety Data

• Hazardous Substances Data: 847728-89-6(Hazardous Substances Data)

Usage

General Description

(S)-[1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is a chemical compound that belongs to the class of carbamic acid esters. It is composed of a tert-butyl ester functional group and a (S)-[1-(4-bromo-phenyl)-ethyl] carbamic acid group. (S)-[1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER is commonly used in chemical research and pharmaceutical synthesis. It may also have potential applications in the field of medicinal and agricultural chemistry. However, as with all chemicals, it is important to handle and use (S)-[1-(4-BROMO-PHENYL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER with care and in accordance with safety guidelines to prevent any potential harm to human health and the environment.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 84499-77-4 (S)-α-(p-bromophenyl)ethylamine hydrochloride 
• 27298-97-1 (S)-1-(4-bromophenyl)ethylamine 

Downstream Products

• 847728-90-9 (S)-methyl 4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate 
• 878805-09-5 1,1-dimethylethyl {(1S)-1-[4-(4-methylpiperazin-1-yl)phenyl]ethyl}carbamate 
• 1556019-43-2 tert-butyl N-[(1S)-1-[4-(trimethylsilylmethylcarbamoyl)phenyl]ethyl]carbamate 
• 1556019-44-3 tert-butyl N-[(1S)-1-[4-(trimethylsilylmethylcarbamothioyl)phenyl]ethyl]carbamate 
• 1556019-46-5 tert-butyl N-[(1S)-1-[4-[5-(3,4,5-trichlorophenyl)-3-(trifluoromethyl)-2,4-dihydropyrrol-3-yl]phenyl]ethyl]carbamate 
• 1014644-95-1 4-[(1S)-1-(tert-butoxycarbonylamino)ethyl]benzoic acid 
• 1038801-13-6 benzyl (2S)-2-[(4-{(1S)-1-[(tert-butoxycarbonyl)amino]ethyl}phenyl)(hydroxy)methyl]-2-methylpyrrolidine-1-carboxylate 
• 1037254-24-2 benzyl (2S)-2-[(4-{(1S)-1-[(tert-butoxycarbonyl)amino]ethyl}phenyl)(hydroxy)methyl]-2-methylpyrrolidine-1-carboxylate 
• 1037251-45-8 tert-butyl [(1S)-1-(4-acetylphenyl)ethyl]carbamate 
• 1037252-24-6 tert-butyl ((1S)-1-{4-[hydroxy(pyridin-2-yl)methyl]phenyl}ethyl)carbamate 
• 1037252-32-6 [(S)-1-(4-formyl-phenyl)ethyl]carbamic acid tertbutyl ester 
• 878805-12-0 t-butyl ((1S)-1-{4-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}ethyl)carbamate 
• 878805-75-5 t-butyl ((1S)-1-{4-[1-(trifluoroacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}ethyl)carbamate 
• 878805-06-2 t-butyl {(1S)-1-[4-(pyrazin-2-ylamino)phenyl]ethyl}carbamate 

Relevant articles and documents

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein

Src homology 2 domain-containing phosphatase 2 (SHP2) is an attractive therapeutic target for human cancers and other human diseases. Herein, we report our discovery of potent small-molecule SHP2 degraders whose design is based upon the proteolysis-targeting chimera (PROTAC) concept. This work has led to the discovery of potent and effective SHP2 degraders, exemplified by SHP2-D26. SHP2-D26 achieves DC50 values of 6.0 and 2.6 nM in esophageal cancer KYSE520 and acute myeloid leukemia MV4;11 cells, respectively, and is capable of reducing SHP2 protein levels by >95% in cancer cells. SHP2-D26 is >30-times more potent in inhibition of phosphorylation of extracellular signal-regulated kinase (ERK) and of cell growth than SHP099, a potent SHP2 inhibitor, in KYSE520 and MV4;11 cancer cell lines. This study demonstrates that induced SHP2 degradation is a very effective approach to inhibit the function of SHP2. Further optimization of these SHP2 degraders may lead to the development of a new class of therapies for cancers and other human diseases.

BRM TARGETING COMPOUNDS AND METHODS OF USE THEREOF

The present invention relates to bifunctional compounds comprising a binding fraction to a target protein and a binding fraction to ubiquitin ligase E3, and associated methods of use.

SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

GPX4 protein degradation agent, preparation method and application thereof, and antitumor cell drug

The invention provides a GPX4 protein degradation agent, a preparation method thereof, and an anti-tumor cell drug, and belongs to the technical field of drug application. The GPX4 protein degradation agent provided by the invention has a protein degradation targeting chimera (PROTAC) molecular structure, a mother nucleus structure of the GPX4 protein degradation agent is used as a small molecule ligand for combining target protein, an A2 substituent is used as a small molecule ligand for combining an E3 ubiquitin ligase compound, and an A1 substituent is used as a connecting group for connecting the two ligands. The GPX4 protein degradation agent with the structure can specifically recognize GPX4 protein and effectively ubiquitinate and degrade the GPX4 protein, so that tumor cell ferroptosis is induced.